Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Patients and Data Collection
2.3. Definitions
2.4. Antimicrobial Prophylaxis
2.5. Statistics
3. Results
3.1. Demographics
3.2. Cumulative Incidence of Infection
3.3. Clinical Manifestation
3.4. Antibiotic Susceptibility and Treatment Outcomes
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Mikulska, M.; Del Bono, V.; Viscoli, C. Bacterial infections in hematopoietic stem cell transplantation recipients. Curr. Opin. Hematol. 2014, 21, 451–458. [Google Scholar] [CrossRef] [PubMed]
- Hakki, M.; Limaye, A.P.; Kim, H.W.; Kirby, K.A.; Corey, L.; Boeckh, M. Invasive Pseudomonas aeruginosa infections: High rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant. 2007, 39, 687–693. [Google Scholar] [CrossRef] [PubMed]
- McCarthy, K.; Paterson, D. Increased risk of death with recurrent Pseudomonas aeruginosa bacteremia. Diagn. Microbiol. Infect. Dis. 2017, 88, 152–157. [Google Scholar] [CrossRef]
- Moradali, M.F.; Ghods, S.; Rehm, B.H.A. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Front. Cell. Infect. Microbiol. 2017, 7, 39. [Google Scholar] [CrossRef]
- Behzadi, P.; Barath, Z.; Gajdacs, M. It’s Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics 2021, 10, 42. [Google Scholar] [CrossRef] [PubMed]
- Puerta-Alcalde, P.; Chumbita, M.; Charry, P.; Castaño-Díez, S.; Cardozo, C.; Moreno-García, E.; Marco, F.; Suárez-Lledó, M.; Garcia-Pouton, N.; Morata, L.; et al. Risk Factors for Mortality in Hematopoietic Stem Cell Transplantation Recipients with Bloodstream Infection: Points To Be Addressed by Future Guidelines. Transplant. Cell. Ther. 2021, 27, 501.e1–501.e6. [Google Scholar] [CrossRef]
- Puerta-Alcalde, P.; Cardozo, C.; Marco, F.; Suárez-Lledó, M.; Moreno, E.; Morata, L.; Fernández-Avilés, F.; Gutiérrez-Garcia, G.; Chumbita, M.; Rosiñol, L.; et al. Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: Current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. Bone Marrow Transplant. 2020, 55, 603–612. [Google Scholar] [CrossRef]
- Gudiol, C.; Garcia-Vidal, C.; Arnan, M.; Sánchez-Ortega, I.; Patiño, B.; Duarte, R.; Carratalà, J. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant. 2014, 49, 824–830. [Google Scholar] [CrossRef]
- Rodríguez, N.; Aguilera-Alonso, D.; Escosa, L.; Gómez-Gil, M.; Manzanares, Á.; Ascaso, M.; Bermejo-Gómez, A.; Ramos, A.; Núñez, A.; Orellana, M.; et al. Pseudomonas aeruginosa bloodstream infections in children and adolescents: Risk factors associated with carbapenem resistance and mortality. J. Hosp. Infect. 2024, 149, 56–64. [Google Scholar] [CrossRef]
- Logan, L.K.; Gandra, S.; Mandal, S.; Klein, E.Y.; Levinson, J.; Weinstein, R.A.; Laxminarayan, R.; Prevention Epicenters Program, US Centers for Disease Control and Prevention. Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa in Children, United States, 1999–2012. J. Pediatr. Infect. Dis. Soc. 2017, 6, 352–359. [Google Scholar]
- Bielicki, J.A.; Lundin, R.; Sharland, M. Antibiotic Resistance Prevalence in Routine Bloodstream Isolates from Children’s Hospitals Varies Substantially from Adult Surveillance Data in Europe. Pediatr. Infect. Dis. J. 2015, 34, 734–741. [Google Scholar] [CrossRef] [PubMed]
- Losito, A.R.; Raffaelli, F.; Del Giacomo, P.; Tumbarello, M. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics 2022, 11, 579. [Google Scholar] [CrossRef] [PubMed]
- Satlin, J.M.; Walsh, J.T. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients. Transpl. Infect. Dis. 2017, 19, 1–29. [Google Scholar] [CrossRef]
- Richert-Przygonska, M.; Czyzewski, K.; Dziedzic, M.; Zalas-Wiecek, P.; Gryniewicz-Kwiatkowska, O.; Gietka, A.; Malas, Z.; Semczuk, K.; Chelmecka, L.; Zak, I.; et al. Infections With Stenotrophomonas maltophilia in Children Undergoing Anticancer Therapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. Pediatr. Infect. Dis. J. 2022, 41, 846–850. [Google Scholar] [CrossRef] [PubMed]
- Sękowska, A.; Czyżewski, K.; Jaremek, K.; Zalas-Więcek, P.; Zając-Spychała, O.; Wachowiak, J.; Szmydki-Baran, A.; Hutnik, Ł.; Gietka, A.; Gryniewicz-Kwiatkowska, O.; et al. Infections with Klebsiella pneumoniae in Children Undergoing Anticancer Therapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. J. Clin. Med. 2024, 13, 4078. [Google Scholar] [CrossRef]
- Magiorakos, A.-P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef]
- Royo-Cebrecos, C.; Laporte-Amargós, J.; Peña, M.; Ruiz-Camps, I.; Puerta-Alcalde, P.; Abdala, E.; Oltolini, C.; Akova, M.; Montejo, M.; Mikulska, M.; et al. Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors. Pathogens 2022, 11, 1132. [Google Scholar] [CrossRef]
- Kikuchi, M.; Akahoshi, Y.; Nakano, H.; Ugai, T.; Wada, H.; Yamasaki, R.; Sakamoto, K.; Kawamura, K.; Ishihara, Y.; Sato, M.; et al. Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. 2015, 17, 56–65. [Google Scholar] [CrossRef]
- Stoma, I.; Karpov, I.; Milanovich, N.; Uss, A.; Iskrov, I. Risk factors for mortality in patients with bloodstream infections during the pre-engraftment period after hematopoietic stem cell transplantation. Blood Res. 2016, 51, 102–106. [Google Scholar] [CrossRef]
- Caselli, D.; Cesaro, S.; Ziino, O.; Zanazzo, G.; Manicone, R.; Livadiotti, S.; Cellini, M.; Frenos, S.; Milano, G.M.; Cappelli, B.; et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010, 95, 1612–1615. [Google Scholar] [CrossRef]
- Viasus, D.; Puerta-Alcalde, P.; Cardozo, C.; Suárez-Lledó, M.; Rodríguez-Núñez, O.; Morata, L.; Fehér, C.; Marco, F.; Chumbita, M.; Moreno-García, E.; et al. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin. Microbiol. Infect. 2020, 26, 345–350. [Google Scholar] [CrossRef]
- Shakerimoghaddam, A.; Moghaddam, A.D.; Barghchi, B.; Sanani, M.G.P.; Azami, P.; Kalmishi, A.; Sabeghi, P.; Motavalli, F.; Khomartash, M.S.; Mousavi, S.H.; et al. Prevalence of Pseudomonas aeruginosa and its antibiotic resistance in patients who have received Hematopoietic Stem-Cell Transplantation; A globally Systematic Review. Microb. Pathog. 2023, 184, 106368. [Google Scholar] [CrossRef]
- Yang, M.A.; Lee, J.; Choi, E.H.; Lee, H.J. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: Analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes. J. Korean Med. Sci. 2011, 26, 612–618. [Google Scholar] [CrossRef] [PubMed]
- Zeng, M.; Xia, J.; Zong, Z.; Shi, Y.; Ni, Y.; Hu, F.; Chen, Y.; Zhuo, C.; Hu, B.; Lv, X.; et al. Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J. Microbiol. Immunol. Infect. 2023, 56, 653–671. [Google Scholar] [CrossRef] [PubMed]
- Sakaguchi, M.; Atsuta, Y.; Sekiya, N.; Najima, Y.; Fukushima, K.; Shingai, N.; Toya, T.; Kobayashi, T.; Ohashi, K.; Doki, N. Clinical impact and early prediction of carbapenem-resistant Pseudomonas aeruginosa bacteraemia in allogeneic hematopoietic stem cell transplantation recipients. J. Glob. Antimicrob. Resist. 2023, 32, 187–194. [Google Scholar] [CrossRef]
- Shields, R.K.; Clancy, C.J.; Pasculle, A.W.; Press, E.G.; Haidar, G.; Hao, B.; Chen, L.; Kreiswirth, B.N.; Nguyen, M.H. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa. J. Clin. Microbiol. 2018, 56, e01093-17. [Google Scholar] [CrossRef] [PubMed]
- Rubio, A.M.; Kline, E.G.; Jones, C.E.; Chen, L.; Kreiswirth, B.N.; Nguyen, M.H.; Clancy, C.J.; Cooper, V.S.; Haidar, G.; Van Tyne, D.; et al. In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. Antimicrob. Agents Chemother. 2021, 65, 1–8. [Google Scholar] [CrossRef]
- Haidar, G.; Philips, N.J.; Shields, R.K.; Snyder, D.; Cheng, S.; Potoski, B.A.; Doi, Y.; Hao, B.; Press, E.G.; Cooper, V.S.; et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clin. Infect. Dis. 2017, 65, 110–120. [Google Scholar] [CrossRef]
PHO Centers (N = 645) | HCT Centers (N = 103) | ||
---|---|---|---|
Diagnosis | Diagnosis | ||
ALL | 247 (38.3%) | ALL | 25 (24.3%) |
AML | 68 (10.5%) | AML | 17 (16.5%) |
Brain tumors | 78 (12.1%) | AA/BMF | 21 (20.4%) |
NHL | 51 (7.9%) | NBL | 15 (14.6%) |
HD | 14 (2.2%) | PID | 12 (11.6%) |
RMS | 32 (4.9%) | Others | 13 (12.6%) |
WT | 19 (2.9%) | ||
NBL | 46 (7.1%) | ||
Others | 90 (14.1%) | ||
Age | Age | ||
(years/median/IQR) | 5.6 (12.2–131) | (years/median/IQR) | 6.8 (3.6–11.2) |
Gender | Gender | ||
Female | 313 (48.5%) | Female | 47 (45.7%) |
Male | 332 (51.5%) | Male | 56 (54.3%) |
Source of infection | Source of infection | ||
BSI | 196 | BSI | 38 |
UTI | 226 | UTI | 39 |
Skin | 88 | Skin | 14 |
Inguinal/perianal | 20 | Inguinal/perianal | |
BAL | 31 | BAL | 1 |
GIT | 42 | Eye | 4 |
Eye | 2 | 2 | |
Ear | 9 | ||
Time to PSA identification (months/median/IQR) | 3.9 (2.1–9.5) | Time to PSA identification (months/median/IQR) | 0.6 (0–4.1) |
Risk Factor | Univariate Analysis (Fine–Gray Model) | Multivariate Analysis (Fine–Gray Model) | ||
---|---|---|---|---|
Subdistribution Hazard (95% CI) | p | Subdistribution Hazard (95% CI) | p | |
Acute leukemia vs. other diagnosis | 1.20 (1.05–1.38) | 0.012 | 1.15 (1.02–1.32) | 0.021 |
Female vs. male | 1.05 (0.91–1.20) | 0.515 | 1.02 (0.87–1.18) | 0.814 |
Age < 10 years vs. ≥10 years | 0.45 (0.27–0.75) | 0.003 | 0.48 (0.30–0.77) | 0.002 |
Time to infection * <5 months vs. ≥5 months | 12.6 (7.2–21.4) | <0.001 | 12.1 (6.7–21.0) | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Richert-Przygońska, M.; Czyżewski, K.; Zalas-Więcek, P.; Gryniewicz-Kwiatkowska, O.; Gietka, A.; Małas, Z.; Semczuk, K.; Chełmecka, L.; Żak, I.; Salamonowicz-Bodzioch, M.; et al. Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. J. Clin. Med. 2025, 14, 3714. https://doi.org/10.3390/jcm14113714
Richert-Przygońska M, Czyżewski K, Zalas-Więcek P, Gryniewicz-Kwiatkowska O, Gietka A, Małas Z, Semczuk K, Chełmecka L, Żak I, Salamonowicz-Bodzioch M, et al. Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. Journal of Clinical Medicine. 2025; 14(11):3714. https://doi.org/10.3390/jcm14113714
Chicago/Turabian StyleRichert-Przygońska, Monika, Krzysztof Czyżewski, Patrycja Zalas-Więcek, Olga Gryniewicz-Kwiatkowska, Agnieszka Gietka, Zofia Małas, Katarzyna Semczuk, Liliana Chełmecka, Iwona Żak, Małgorzata Salamonowicz-Bodzioch, and et al. 2025. "Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study" Journal of Clinical Medicine 14, no. 11: 3714. https://doi.org/10.3390/jcm14113714
APA StyleRichert-Przygońska, M., Czyżewski, K., Zalas-Więcek, P., Gryniewicz-Kwiatkowska, O., Gietka, A., Małas, Z., Semczuk, K., Chełmecka, L., Żak, I., Salamonowicz-Bodzioch, M., Frączkiewicz, J., Zając-Spychała, O., Bień, E., Irga-Jaworska, N., Płonowski, M., Wawryków, P., Bartnik, M., Pierlejewski, F., Gamrot, Z., ... Styczyński, J., on behalf of the Polish Society of Pediatric Oncology and Hematology. (2025). Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. Journal of Clinical Medicine, 14(11), 3714. https://doi.org/10.3390/jcm14113714